Ines De Pauw

591 total citations
18 papers, 413 citations indexed

About

Ines De Pauw is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ines De Pauw has authored 18 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Ines De Pauw's work include Lung Cancer Treatments and Mutations (7 papers), Cancer-related Molecular Pathways (5 papers) and HER2/EGFR in Cancer Research (4 papers). Ines De Pauw is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer-related Molecular Pathways (5 papers) and HER2/EGFR in Cancer Research (4 papers). Ines De Pauw collaborates with scholars based in Belgium and Netherlands. Ines De Pauw's co-authors include Marc Peeters, An Wouters, Filip Lardon, Jan B. Vermorken, Patrick Pauwels, Jolien Van den Bossche, Vanessa Deschoolmeester, Pol Specenier, Jorrit De Waele and Julie Jacobs and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and Frontiers in Immunology.

In The Last Decade

Ines De Pauw

18 papers receiving 410 citations

Peers

Countries citing papers authored by Ines De Pauw

Since Specialization

Citations

This map shows the geographic impact of Ines De Pauw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ines De Pauw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ines De Pauw more than expected).

Fields of papers citing papers by Ines De Pauw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ines De Pauw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ines De Pauw. The network helps show where Ines De Pauw may publish in the future.

Co-authorship network of co-authors of Ines De Pauw

This figure shows the co-authorship network connecting the top 25 collaborators of Ines De Pauw. A scholar is included among the top collaborators of Ines De Pauw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ines De Pauw. Ines De Pauw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity 2023 ·Cancer Drug Resistance ·(unknown), Ines De Pauw, (unknown), (unknown), (unknown), Christophe Hermans, (unknown), Hilde Lambrechts, Céline Merlin, Cyril Corbet, Marc Peeters, Jan B. Vermorken, Jorrit De Waele, Filip Lardon, An Wouters	2
2	The prognostic impact of the immune signature in head and neck squamous cell carcinoma 2022 ·Frontiers in Immunology ·(unknown), Vasiliki Siozopoulou, (unknown), Christophe Hermans, (unknown), Hilde Lambrechts, Erik Fransén, Ines De Pauw, Julie Jacobs, Marc Peeters, Patrick Pauwels, Jan B. Vermorken, Evelien Smits, Filip Lardon, Jorrit De Waele, An Wouters	13
3	Prognostic implications of cellular senescence in resected non-small cell lung cancer 2022 ·Translational Lung Cancer Research ·Andreas Domen, Christophe Deben, Ines De Pauw, Christophe Hermans, Hilde Lambrechts, (unknown), Vasiliki Siozopoulou, Patrick Pauwels, Marco Demaria, (unknown), Annelies Janssens, Jeroen Hendriks, Paul Van Schil, Jan B. Vermorken, Timon Vandamme, Hans Prenen, Marc Peeters, Filip Lardon, An Wouters	29
4	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies 2021 ·Frontiers in Immunology ·(unknown), Ines De Pauw, (unknown), Marc Peeters, Jan B. Vermorken, Filip Lardon, Jorrit De Waele, An Wouters	39
5	The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy 2021 ·Frontiers in Oncology ·(unknown), Ines De Pauw, (unknown), Patrick Pauwels, Marc Peeters, Jan B. Vermorken, Filip Lardon, An Wouters	13
6	Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma 2021 ·Medicinal Research Reviews ·(unknown), Ines De Pauw, (unknown), Marc Peeters, Jan B. Vermorken, Filip Lardon, An Wouters	46
7	Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status 2020 ·British Journal of Cancer ·(unknown), Ines De Pauw, (unknown), Jorrit De Waele, Marc Peeters, Patrick Pauwels, Jan B. Vermorken, Evelien Smits, Filip Lardon, Julie Jacobs, An Wouters	29
8	Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib 2019 ·Cancers ·Ines De Pauw, Filip Lardon, Jolien Van den Bossche, (unknown), Patrick Pauwels, Marc Peeters, Jan B. Vermorken, An Wouters	14
9	Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status 2019 ·Cancers ·Jolien Van den Bossche, Andreas Domen, Marc Peeters, Christophe Deben, Ines De Pauw, Julie Jacobs, (unknown), Pol Specenier, Patrick Pauwels, Jan B. Vermorken, Filip Lardon, An Wouters	9
10	In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53 2019 ·Molecular Oncology ·Jolien Van den Bossche, Christophe Deben, Ines De Pauw, Hilde Lambrechts, Christophe Hermans, Vanessa Deschoolmeester, Julie Jacobs, Pol Specenier, Patrick Pauwels, Jan B. Vermorken, Marc Peeters, Filip Lardon, An Wouters	15
11	Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines 2018 ·Molecular Oncology ·Ines De Pauw, Filip Lardon, Jolien Van den Bossche, (unknown), Erik Fransén, Vanessa Deschoolmeester, Patrick Pauwels, Marc Peeters, Jan B. Vermorken, An Wouters	35
12	Enzymes Catalyzing the TCA- and Urea Cycle Influence the Matrix Composition of Biofilms Formed by Methicillin-Resistant Staphylococcus aureus USA300 2018 ·Microorganisms ·(unknown), Julia Sabirova, Ines De Pauw, Henri De Greve, Jean-Pierre Hernálsteens, Herman Goossens, Surbhi Malhotra‐Kumar	28
13	Identification of resistance mechanisms for EGFR-targeted therapy in head and neck squamous cell carcinoma: Combining whole-exome sequencing and tumour kinase profiling 2018 ·Annals of Oncology ·Ines De Pauw, An Wouters, Jolien Van den Bossche, Ken Op de Beeck, Matthias Beyens, (unknown), Patrick Pauwels, Marc Peeters, J. B. Vermorken, Filip Lardon	1
14	Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia 2017 ·Journal of Cancer ·Jolien Van den Bossche, Christophe Deben, Ken Op de Beeck, Vanessa Deschoolmeester, Christophe Hermans, Ines De Pauw, Julie Jacobs, Paul Van Schil, Jan B. Vermorken, Patrick Pauwels, Marc Peeters, Filip Lardon, An Wouters	12
15	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines 2017 ·Cancer Biotherapy and Radiopharmaceuticals ·Ines De Pauw, An Wouters, Jolien Van den Bossche, Vanessa Deschoolmeester, (unknown), Patrick Pauwels, Marc Peeters, Jan B. Vermorken, Filip Lardon	13
16	Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer 2016 ·Pharmacology & Therapeutics ·Ines De Pauw, An Wouters, Jolien Van den Bossche, Marc Peeters, Patrick Pauwels, Vanessa Deschoolmeester, Jan B. Vermorken, Filip Lardon	13
17	Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor 2016 ·Medicinal Research Reviews ·Jolien Van den Bossche, Filip Lardon, Vanessa Deschoolmeester, Ines De Pauw, Jan B. Vermorken, Pol Specenier, Patrick Pauwels, Marc Peeters, An Wouters	83
18	The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines 2015 ·BMC Research Notes ·Carolien Boeckx, Jolien Van den Bossche, Ines De Pauw, Marc Peeters, Filip Lardon, Marc Baay, An Wouters	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact